舒尼替尼一线治疗晚期肾癌的疗效及安全性观察分析

Clinical Observation of Sunitinib for the First Line Treatment for Patients with Advanced Renal Cell Carcinoma

观察分析舒尼替尼一线治疗晚期肾癌的疗效及安全性。回顾性分析大连医科大学附属第一医院泌尿外科收治的晚期肾癌患者32例，男20例，女12例。32例均行原发肿瘤切除术，病理类型均为透明细胞癌。进行疗效及安全性观察，分析总体生存时间及疾病无进展生存时间。随访10个月-36个月，平均19个月，可评价疗效32例，病情完全缓解3例（9.4％），部分缓解9例（28.1％），病情稳定17例（50.0％），疾病进展3例（12.5％）。中位无进展生存期13个月（95％CI：10.1个月-15.4个月），中位总生存期23个月（95％CI：16.7个月-28.5个月）。疾病控制率87.5％，客观缓解率37.5％。不良事件多为Ⅰ级-Ⅱ级，管理后可缓解，Ⅲ级不良反应少见，共9例（28.1%），未见Ⅳ级及Ⅴ级不良反应。舒尼替尼一线治疗晚期肾癌有良好的治疗效果，安全性较高。

To evaluate and analyze the efficacy and side effects with sunitinib in the first line treatment of advanced renal cell carcinoma. A retrospective analysis about 32 patients with advanced renal cell carcinoma administered sunitinib with the first line treatment,included 20 male and 12 female patients. All 32 patients had radical nephrectomy,and all of them were clear-cell RCC. Evaluated efficacy and side effects of them, and the overall survival （OS） and progressive-free survival （PFS） were analyzed. The averaged follow-up time was 19 months, range from 10 to 36 months. Clinical efficacy could be evaluated in all 32 cases. Three of them achieved complete response （9.4%）,nine patients were partial response （28.1%）,seventeen （50%） cases demonstrated stable and three （12.5%） developed disease progression. The median PFS was 13 months and the median OS was 23 months. The disease control rate was 87.5% and the ORR was 37.5%. Most of the adverse events were grade Ⅰ or Ⅱ,could be alleviated by management. Grade Ⅲ adverse events 9（28.1%） were infrequent, grade Ⅳ and Ⅴ adverse events did not occur. There ware good efficacy and safety in the first line treatment with sunitinib in advanced renal cell carcinoma.